Menu Search
Equities

IHH Healthcare Bhd

Q0F:SES

IHH Healthcare Bhd

Actions
Health CareHealth Care Providers
  • Price (SGD)1.79
  • Today's Change0.03 / 1.70%
  • Shares traded218.40k
  • 1 Year change+4.68%
  • Beta0.2610
Data delayed at least 10 minutes, as of Apr 26 2024 09:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IHH Healthcare Berhad is a Malaysia-based integrated healthcare provider. The Company's segments include Hospital and Healthcare, IMU Health, Labs, PLife REIT and Others. It operates its Hospital and Healthcare segment in Singapore, Malaysia, India, Greater China, Turkey and Europe and Southeast Asia. The IMU Health segment is engaged in providing educational services. The Labs segment provides diagnostic laboratory services. The PLife REIT segment is a real estate investment trust. Through its portfolio of brands, such as Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway, the Company offers its patients comprehensive and personalized care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging, and rehabilitation. It provides day-to-day healthcare services through outpatient treatment, routine check-ups, and vaccinations. Its secondary care comprises specialist consultation, local surgeries, and others.

  • Revenue in MYR (TTM)20.93bn
  • Net income in MYR2.95bn
  • Incorporated2010
  • Employees65.00k
  • Location
    IHH Healthcare BhdLevel 11 Block APantai Hospital Kuala Lumpur8 Jalan Bukit PantaiKUALA LUMPUR 59100MalaysiaMYS
  • Phone+60 322989898
  • Fax+60 322989899
  • Websitehttps://www.ihhhealthcare.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.